• Veeco Reports First Quarter 2022 Financial Results

    Source: Nasdaq GlobeNewswire / 09 May 2022 16:05:01   America/New_York

    First Quarter 2022 Highlights:

    • Revenues of $156.4 million, compared with $133.7 million in the same period last year
    • GAAP net income of $13.3 million, or $0.24 per diluted share, compared with $2.5 million, or $0.05 per diluted share in the same period last year
    • Non-GAAP net income of $21.7 million, or $0.38 per diluted share, compared with $12.6 million, or $0.25 per diluted share in the same period last year

    PLAINVIEW, N.Y., May 09, 2022 (GLOBE NEWSWIRE) -- Veeco Instruments Inc. (Nasdaq: VECO) today announced financial results for its first quarter ended March 31, 2022. Results are reported in accordance with U.S. generally accepted accounting principles (“GAAP”) and are also reported adjusting for certain items (“Non-GAAP”). A reconciliation between GAAP and Non-GAAP operating results is provided at the end of this press release.

     
    U.S. Dollars in millions, except per share data
      1st Quarter
       
         
    GAAP Results Q1 '22 Q1 '21
         
       
         
         
    Revenue $156.4 $133.7
    Net income $13.3 $2.5
    Diluted earnings per share $0.24 $0.05


      1st Quarter
       
         
    Non-GAAP Results Q1 '22 Q1 '21
       
         
    Operating income $24.7 $16.1
    Net income $21.7 $12.6
    Diluted earnings per share $0.38 $0.25
           

    “Veeco is experiencing healthy demand for our products and we delivered solid first quarter results above the midpoint of our guidance, with revenue growing 17% from the first quarter last year,” commented Bill Miller, Veeco’s Chief Executive Officer. “Consistent with our growth strategy, sales in both our Semiconductor and Compound Semiconductor markets increased 50% over the same time period.”

    “While facing industry-wide cost increases and supply chain disruptions related to inbound material lead times, logistics and labor, the Veeco United team is working diligently to meet our customers’ increasing demands. Looking at the full year, we are on pace to deliver on our 2022 revenue target.”

    Guidance and Outlook

    The following guidance is provided for Veeco’s second quarter 2022:

    • Revenue is expected in the range of $150 million to $170 million
    • GAAP diluted earnings per share are expected in the range of $0.05 to $0.19
    • Non-GAAP diluted earnings per share are expected in the range of $0.22 to $0.34

    Conference Call Information

    A conference call reviewing these results has been scheduled for today, May 9, 2022 starting at 5:00pm ET. To join the call, dial 1-888-220-8451 (toll free) or 1-646-828-8193 and use passcode 9557580. Participants may also access a live webcast of the call by visiting the investor relations section of Veeco's website at ir.veeco.com. A replay of the webcast will be made available on the Veeco website that evening. We will post an accompanying slide presentation to our website prior to the beginning of the call.

    About Veeco

    Veeco (NASDAQ: VECO) is an innovative manufacturer of semiconductor process equipment. Our proven ion beam, laser annealing, lithography, MOCVD, and single wafer etch & clean technologies play an integral role in the fabrication and packaging of advanced semiconductor devices. With equipment designed to optimize performance, yield and cost of ownership, Veeco holds leading technology positions in the markets we serve. To learn more about Veeco’s systems and service offerings, visit www.veeco.com.

    Forward-looking Statements

    This press release contains “forward-looking statements”, within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, as amended, that are based on management’s expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “plans,” “believes,” “scheduled,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements. Forward-looking statements include, but are not limited to, those regarding anticipated growth and trends in our businesses and markets, industry outlooks and demand drivers, our investment and growth strategies, our development of new products and technologies, our business outlook for current and future periods, the impact of the COVID-19 pandemic, our ongoing transformation initiative and the effects thereof on our operations and financial results; and other statements that are not historical facts. These statements and their underlying assumptions are subject to risks and uncertainties and are not guarantees of future performance. Factors that could cause actual results to differ materially from those expressed or implied by such statements include, without limitation: the level of demand for our products; global economic and industry conditions; the effects of regional or global health epidemics, including the effects of the COVID-19 pandemic on the Company’s operations and on those of our customers and suppliers; global trade issues, including the ongoing trade disputes between the U.S. and China, and changes in trade and export license policies; our dependency on third-party suppliers and outsourcing partners; the timing of customer orders; our ability to develop, deliver and support new products and technologies; our ability to expand our current markets, increase market share and develop new markets; the concentrated nature of our customer base; our ability to obtain and protect intellectual property rights in key technologies; our ability to achieve the objectives of operational and strategic initiatives and attract, motivate and retain key employees; the variability of results among products and end-markets, and our ability to accurately forecast future results, market conditions, and customer requirements; the impact of our indebtedness, including our convertible senior notes and our capped call transactions; and other risks and uncertainties described in our SEC filings on Forms 10-K, 10-Q and 8-K, and from time-to-time in our other SEC reports. All forward-looking statements speak only to management’s expectations, estimates, projections and assumptions as of the date of this press release or, in the case of any document referenced herein or incorporated by reference, the date of that document. The Company does not undertake any obligation to update or publicly revise any forward-looking statements to reflect events, circumstances or changes in expectations after the date of this press release.

    -financial tables attached-

    Veeco Contacts:   
        
    Investors:Anthony Bencivenga(516) 252-1438abencivenga@veeco.com
    Media:Kevin Long(516) 714-3978klong@veeco.com
        


    Veeco Instruments Inc. and Subsidiaries

    Condensed Consolidated Statements of Operations
    (in thousands, except per share amounts)
    (unaudited)

          
     Three months ended March 31,
     2022     2021 
    Net sales$156,426  $133,714 
    Cost of sales 90,413   78,800 
    Gross profit 66,013   54,914 
    Operating expenses, net:     
    Research and development 24,117   21,844 
    Selling, general, and administrative 22,894   20,255 
    Amortization of intangible assets 2,504   3,354 
    Other operating expense (income), net (19)  46 
    Total operating expenses, net 49,496   45,499 
    Operating income 16,517   9,415 
    Interest expense, net (2,803)  (6,623)
    Income before income taxes 13,714   2,792 
    Income tax expense (benefit) 384   298 
    Net income$13,330  $2,494 
          
    Income per common share:     
    Basic$0.27  $0.05 
    Diluted$0.24  $0.05 
          
    Weighted average number of shares:     
    Basic 49,614   48,624 
    Diluted 65,285   53,050 
            


    Veeco Instruments Inc. and Subsidiaries
    Condensed Consolidated Balance Sheets
    (in thousands)

          
     March 31,  December 31,
     2022    2021
     (unaudited)   
    Assets     
    Current assets:     
    Cash and cash equivalents$127,624 $119,747
    Restricted cash 688  725
    Short-term investments 103,277  104,181
    Accounts receivable, net 99,479  109,609
    Contract assets 25,602  18,293
    Inventories 179,066  170,858
    Prepaid expenses and other current assets 34,214  25,974
    Total current assets 569,950  549,387
    Property, plant and equipment, net 104,128  99,743
    Operating lease right-of-use assets 27,800  28,813
    Intangible assets, net 31,401  33,905
    Goodwill 181,943  181,943
    Deferred income taxes 1,639  1,639
    Other assets 3,503  3,546
    Total assets$920,364 $898,976
          
    Liabilities and stockholders’ equity     
    Current liabilities:     
    Accounts payable$56,154 $44,456
    Accrued expenses and other current liabilities 80,920  79,752
    Customer deposits and deferred revenue 61,893  63,136
    Income taxes payable 1,633  1,860
    Current portion of long-term debt 20,096  
    Total current liabilities 220,696  189,204
    Deferred income taxes 4,780  4,792
    Long-term debt 253,840  229,438
    Long-term operating lease liabilities 32,410  32,834
    Other liabilities 5,068  5,080
    Total liabilities 516,794  461,348
          
    Total stockholders’ equity 403,570  437,628
    Total liabilities and stockholders’ equity$920,364 $898,976
          


    Note on Reconciliation Tables

    The below tables include financial measures adjusted for the impact of certain items; these financial measures are therefore not calculated in accordance with U.S. generally accepted accounting principles (“GAAP”). These Non-GAAP financial measures exclude items such as: share-based compensation expense; charges relating to restructuring initiatives; non-cash asset impairments; certain other non-operating gains and losses; and acquisition-related items such as transaction costs, non-cash amortization of acquired intangible assets, and certain integration costs.

    These Non-GAAP financial measures may be different from Non-GAAP financial measures used by other companies. Non-GAAP financial measures should not be considered a substitute for, or superior to, measures of financial performance prepared in accordance with GAAP. By excluding these items, Non-GAAP financial measures are intended to facilitate meaningful comparisons to historical operating results, competitors’ operating results, and estimates made by securities analysts. Management is evaluated on key performance metrics including Non-GAAP Operating income (loss), which is used to determine management incentive compensation as well as to forecast future periods. These Non-GAAP financial measures may be useful to investors in allowing for greater transparency of supplemental information used by management in its financial and operational decision-making. In addition, similar Non-GAAP financial measures have historically been reported to investors; the inclusion of comparable numbers provides consistency in financial reporting. Investors are encouraged to review the reconciliation of the Non-GAAP financial measures used in this news release to their most directly comparable GAAP financial measures.


    Reconciliation of GAAP to Non-GAAP Financial Data (Q1 2022)
    (in thousands)
    (unaudited)

                  
         Non-GAAP Adjustments    
              
         Share-Based        
    Three months ended March 31, 2022    GAAP    Compensation    Amortization    Other    Non-GAAP 
                
    Net sales $156,426       $156,426 
    Gross profit  66,013 938    534   67,485 
    Gross margin  42.2%       43.1%
    Operating expenses  49,496 (3,543) (2,504) (691)  42,758 
                     
    Operating income  16,517 4,481  2,504  1,225 ^ 24,727 
    Net income  13,330 4,481  2,504  1,387 ^ 21,702 

    ___________________________
    ^  - See table below for additional details.


    Other Non-GAAP Adjustments (Q1 2022)
    (in thousands)
    (unaudited)

       
    Three months ended March 31, 2022     
    Transition expenses related to San Jose expansion project$1,165 
    Depreciation of PP&E fair value step-up associated with the Ultratech purchase accounting 60 
    Subtotal 1,225 
    Non-cash interest expense 237 
    Non-GAAP tax adjustment * (75)
    Total Other$1,387 

    ___________________________
    *  - The ‘with or without’ method is utilized to determine the income tax effect of all Non-GAAP adjustments.


    Net Income per Common Share (Q1 2022)
    (in thousands, except per share amounts)
    (unaudited)

          
     Three months ended March 31, 2022
     GAAP Non-GAAP
    Numerator:     
    Net income$13,330    $21,702
    Interest expense associated with convertible notes 2,544  2,467
    Net income available to common shareholders$15,874 $24,169
          
    Denominator:     
    Basic weighted average shares outstanding 49,614  49,614
    Effect of potentially dilutive share-based awards 1,208  1,208
    Dilutive effect of 2023 Convertible Senior Notes   504
    Dilutive effect of 2025 Convertible Senior Notes 5,521  5,521
    Dilutive effect of 2027 Convertible Senior Notes (1) 8,942  6,771
    Diluted weighted average shares outstanding 65,285  63,618
          
    Net income per common share:     
    Basic$0.27 $0.44
    Diluted$0.24 $0.38

    ___________________________
    (1)
      - The non-GAAP incremental dilutive shares includes the impact of the Company’s capped call transaction issued concurrently with our 2027 Notes, and as such, an effective conversion price of $18.46 is used when determining incremental shares to add to the dilutive share count. The GAAP incremental dilutive shares does not include the impact of the Company’s capped call transaction, and as such, an effective conversion price of $13.98 is used when determining incremental shares to add to the dilutive share count.


    Reconciliation of GAAP to Non-GAAP Financial Data (Q1 2021)
    (in thousands, except per share amounts)
    (unaudited)

                  
         Non-GAAP Adjustments    
         Share-based       
    Three months ended March 31, 2021     GAAP    Compensation    Amortization    Other    Non-GAAP 
    Net sales $133,714       $133,714 
    Gross profit  54,914 495    32   55,441 
    Gross margin  41.1%         41.5%
    Operating expenses  45,499 (2,742) (3,354) (73)  39,330 
    Operating income  9,415 3,237  3,354  105 ^ 16,111 
    Net income  2,494 3,237  3,354  3,544 ^ 12,629 
                  
    Income per common share:             
    Basic $0.05       $0.26 
    Diluted  0.05        0.25 
    Weighted average number of shares:             
    Basic  48,624        48,624 
    Diluted (1)  53,050        50,880 

    ___________________________
    ^   - See table below for additional details.

    (1)  - The non-GAAP incremental dilutive shares includes the impact of the Company’s capped call transaction issued concurrently with our 2027 Notes, and as such, no incremental shares are added to the dilutive share count in periods in which the average stock price per share is below $18.46. The GAAP incremental dilutive shares does not include the impact of the Company’s capped call transaction, and as such, incremental shares are added to the dilutive share count in periods in which the average stock price per share is above $13.98, and the Company is in a net income position. The average stock price for the three months ended March 31, 2021 was $20.80, and therefore 0.8 million shares were included in the non-GAAP diluted share count, and 2.9 million shares were included in the GAAP diluted share count related to the 2027 Notes.


    Other Non-GAAP Adjustments (Q1 2021)
    (in thousands)
    (unaudited)

       
    Three months ended March 31, 2021  
    Depreciation of PP&E fair value step-up associated with the Ultratech purchase accounting$96 
    Other 9 
    Subtotal 105 
    Non-cash interest expense 3,514 
    Non-GAAP tax adjustment * (75)
    Total Other$3,544 

    ___________________________
    *  - The ‘with or without’ method is utilized to determine the income tax effect of all Non-GAAP adjustments.


    Reconciliation of GAAP Net Income to Non-GAAP Operating Income (Q1 2022 and 2021)
    (in thousands)
    (unaudited)

          
     Three months ended     Three months ended
     March 31, 2022 March 31, 2021
    GAAP Net income$13,330 $2,494
    Share-based compensation 4,481  3,237
    Amortization 2,504  3,354
    Transition expenses related to San Jose expansion project 1,165  
    Depreciation of PP&E fair value step-up associated with the Ultratech purchase accounting 60  96
    Interest (income) expense, net 2,803  6,623
    Income tax expense (benefit) 384  298
    Other   9
    Non-GAAP Operating income$24,727 $16,111
          


    Reconciliation of GAAP to Non-GAAP Financial Data (Q2 2022)
    (in millions, except per share amounts)
    (unaudited)

                            
              Non-GAAP Adjustments         
    Guidance for the three months ending         Share-based              
    June 30, 2022 GAAP Compensation Amortization    Other     Non-GAAP 
    Net sales    $150     -    $170                    $150     -    $170  
    Gross profit  58  -  67  1    1   60  -  69  
    Gross margin  38% -  39%        40% -  41% 
    Operating expenses  51  -  53  (4) (3) (1)  44  -  46  
    Operating income  6  -  13  5  3  1   15  -  22  
    Net income $3  - $10  5  3  1  $12  - $19  
                            
    Income per diluted common share $0.05  - $0.19           $0.22  - $0.34  
                                


    Income per Diluted Common Share (Q2 2022)
    (in millions, except per share amounts)
    (unaudited)

                     
    Guidance for the three months ending June 30, 2022 GAAP Non-GAAP
    Numerator:                
    Net income    $3    -    $10    $12    -    $19
    Interest expense associated with convertible notes      1  2    2
    Net income available to common shareholders $3 - $11 $14 - $21
                     
    Denominator:                
    Basic weighted average shares outstanding  49    49  49    49
    Effect of potentially dilutive share-based awards  2    2  2    2
    Dilutive effect of 2023 Convertible Senior Notes            
    Dilutive effect of 2025 Convertible Senior Notes        6    6
    Dilutive effect of 2027 Convertible Senior Notes (1)      9  7    7
    Diluted weighted average shares outstanding  51    60  64    64
                     
    Net income per common share:                
    Income per diluted common share $0.05 - $0.19 $0.22 - $0.34

    ___________________________
    (1)
      - The non-GAAP incremental dilutive shares includes the impact of the Company’s capped call transaction issued concurrently with our 2027 Notes, and as such, an effective conversion price of $18.46 is used when determining incremental shares to add to the dilutive share count. The GAAP incremental dilutive shares does not include the impact of the Company’s capped call transaction, and as such, an effective conversion price of $13.98 is used when determining incremental shares to add to the dilutive share count.


    Reconciliation of GAAP Net Income to Non-GAAP Operating Income (Q2 2022)
    (in millions)
    (unaudited)

             
    Guidance for the three months ending June 30, 2022                 
    GAAP Net income $3 - $10
    Share-based compensation  5 -  5
    Amortization  3 -  3
    Interest expense, net  3 -  3
    Other  1 -  1
    Non-GAAP Operating income $15 - $22

    Note: Amounts may not calculate precisely due to rounding. 


    Primary Logo

Share on,